Optimizing Opioid Use Disorder Treatment: When Does 300 mg Outperform 100 mg of Extended-Release Buprenorphine?
Posted innews Psychiatry Public Health

Optimizing Opioid Use Disorder Treatment: When Does 300 mg Outperform 100 mg of Extended-Release Buprenorphine?

This randomized clinical trial compares 100-mg and 300-mg maintenance doses of extended-release buprenorphine. While overall efficacy was similar, the 300-mg dose significantly improved abstinence among patients with high-frequency fentanyl use, suggesting a need for dose-intensification in the era of potent synthetic opioids.
CBT‑I in Cancer Survivors: Small Subjective Gains, Unclear Objective Benefits — What the 2025 Cochrane Review Tells Clinicians
Posted innews Oncology Psychiatry

CBT‑I in Cancer Survivors: Small Subjective Gains, Unclear Objective Benefits — What the 2025 Cochrane Review Tells Clinicians

A 2025 Cochrane review of 21 RCTs (2431 participants) finds cognitive behavioural therapy for insomnia (CBT‑I) yields modest improvements in self‑reported insomnia and sleep quality in people with cancer versus inactive controls or aerobic activity; objective sleep changes and long‑term effects remain uncertain.
Tailored Digital Emotion Regulation Improves Mental Health in Adults With Congenital Heart Disease: Results of a National Randomized Trial
Posted inCardiology news Psychiatry

Tailored Digital Emotion Regulation Improves Mental Health in Adults With Congenital Heart Disease: Results of a National Randomized Trial

A 3‑arm randomized trial in 524 adults with congenital heart disease found a 4‑week tailored digital emotion‑regulation program produced moderate improvements in emotion regulation and multiple psychosocial outcomes versus usual care; a general program showed delayed, smaller benefits.
School Feeding Programs: Comprehensive Evidence on Benefits for Socioeconomically Disadvantaged School Children’s Physical and Psychological Health
Posted inClinical Updates news Pediatrics Psychiatry Public Health

School Feeding Programs: Comprehensive Evidence on Benefits for Socioeconomically Disadvantaged School Children’s Physical and Psychological Health

This review synthesizes global evidence, including meta-analyses, showing that school feeding programs modestly improve math achievement, enrollment, and growth metrics in socioeconomically disadvantaged children, with limited effects on reading or attendance, and uncertain impact on overweight/obesity.
Large Phase 3 Trials Show No Cognitive Benefit with Iclepertin in Schizophrenia — What the CONNEX Programme Teaches Us About Treating CIAS
Posted innews Psychiatry

Large Phase 3 Trials Show No Cognitive Benefit with Iclepertin in Schizophrenia — What the CONNEX Programme Teaches Us About Treating CIAS

Three multinational phase 3 trials found no clinically meaningful cognitive benefit of the GlyT1 inhibitor iclepertin versus placebo in schizophrenia, though the drug was well tolerated. Results highlight methodological and biological challenges in developing treatments for cognitive impairment associated with schizophrenia.
Metformin Moderately Reduces Antipsychotic-Related Weight Gain in Youth with Bipolar Spectrum Disorders: Large Pragmatic 24‑Month Trial Supports Clinical Use
Posted innews Pediatrics Psychiatry

Metformin Moderately Reduces Antipsychotic-Related Weight Gain in Youth with Bipolar Spectrum Disorders: Large Pragmatic 24‑Month Trial Supports Clinical Use

A 1,565‑participant pragmatic randomized trial shows metformin added to lifestyle counseling produced modest but statistically significant reductions in BMI Z-score at 6 and 24 months in overweight/obese children and adolescents with bipolar spectrum disorders taking second‑generation antipsychotics.
Metformin Modestly Reduces Antipsychotic-Associated Weight Gain in Youth with Bipolar Spectrum Disorders — Large Pragmatic Trial Supports Consideration in Practice
Posted innews Pediatrics Psychiatry

Metformin Modestly Reduces Antipsychotic-Associated Weight Gain in Youth with Bipolar Spectrum Disorders — Large Pragmatic Trial Supports Consideration in Practice

A large, pragmatic randomized trial found that adjunctive metformin produced a modest but statistically significant reduction in BMI Z-score at 6 and 24 months among overweight and obese youth with bipolar spectrum disorders treated with second-generation antipsychotics.
Stopping Smoking Is Associated With Better Recovery From Other Substance Use Disorders: Longitudinal Evidence From a US National Cohort
Posted innews Psychiatry Public Health

Stopping Smoking Is Associated With Better Recovery From Other Substance Use Disorders: Longitudinal Evidence From a US National Cohort

A longitudinal, nationally representative cohort study found that within-person transition from current to former cigarette smoking was associated with a 30–43% higher odds of sustained recovery from other substance use disorders, supporting integration of smoking cessation into SUD care.